Pathologic and Gene Expression Features of Metastatic Melanomas to the Brain

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2013 May 23

PMID 23695963

Citations 23

Authors

Ronald Hamilton

Michal Krauze

Marjorie Romkes

Bernard Omolo

Panagiotis Konstantinopoulos

Todd Reinhart

Malgorzata Harasymczuk

Yangyang Wang

Yan Lin

Soldano Ferrone

Theresa Whiteside

Stephanie Bortoluzzi

Jonette Werley

Tomoko Nukui

Beth Fallert-Junecko

Douglas Kondziolka

Joseph Ibrahim

Dorothea Becker

John Kirkwood

Stergios Moschos

Affiliations

Soon will be listed here.

Abstract

Background: The prognosis of metastatic melanomas to the brain (MBM) is variable with prolonged survival in a subset. It is unclear whether MBM differ from extracranial metastases (EcM) and primary melanomas (PrM).

Methods: To study the biology of MBM, histopathologic analysis of tumor blocks from patients' craniotomy samples and whole-genome expression profiling (WGEP) with confirmatory immunohistochemistry were performed.

Results: High mononuclear infiltrate and low intratumoral hemorrhage were associated with prolonged overall survival (OS). Pathway analysis of WGEP data from 29 such craniotomy tumor blocks demonstrated that several immune-related BioCarta gene sets were associated with prolonged OS. WGEP analysis of MBM in comparison with same-patient EcM and PrM showed that MBM and EcM were similar, but both differ significantly from PrM. Immunohistochemical analysis revealed that peritumoral CD3⁺ and CD8⁺ cells were associated with prolonged OS.

Conclusions: MBMs are more similar to EcM compared with PrM. Immune infiltrate is a favorable prognostic factor for MBM.

Citing Articles

Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases.

Chew Minmin S, Bacotti A, Chen Y, Anders C, Sambade M, Deal A Breast Cancer Res Treat. 2023; 199(1):99-107.

PMID: 36930347 PMC: 10865424. DOI: 10.1007/s10549-023-06908-0.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins M, Boire A Pigment Cell Melanoma Res. 2022; 35(6):554-572.

PMID: 35912544 PMC: 10171356. DOI: 10.1111/pcmr.13059.

Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents.

Moschos S Am J Clin Dermatol. 2022; 23(4):523-545.

PMID: 35534670 DOI: 10.1007/s40257-022-00678-z.

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

Lau P, Feran B, Smith L, Lasocki A, Molania R, Smith K J Immunother Cancer. 2021; 9(10).

PMID: 34625515 PMC: 8504361. DOI: 10.1136/jitc-2021-002995.

Re-thinking therapeutic development for CNS metastatic disease.

Saberian C, Davies M Exp Dermatol. 2021; 31(1):74-81.

PMID: 34152638 PMC: 11373440. DOI: 10.1111/exd.14413.

References

Lin Q, Balasubramanian K, Fan D, Kim S, Guo L, Wang H . Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010; 12(9):748-54. PMC: 2933695. DOI: 10.1593/neo.10602. View

Katagata Y, Kondo S . Keratin expression and its significance in five cultured melanoma cell lines derived from primary, recurrent and metastasized melanomas. FEBS Lett. 1997; 407(1):25-31. DOI: 10.1016/s0014-5793(97)00290-1. View

Yu B, Zhang W . Down-regulation of CD3zeta is a breast cancer biomarker associated with immune suppression. Cell Biol Int. 2010; 35(2):165-9. DOI: 10.1042/CBI20100346. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Jakob J, Bassett Jr R, Ng C, Curry J, Joseph R, Alvarado G . NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2011; 118(16):4014-23. PMC: 3310961. DOI: 10.1002/cncr.26724. View

Reinhart T, Rogan M, Huddleston D, Rausch D, Eiden L, Haase A . Simian immunodeficiency virus burden in tissues and cellular compartments during clinical latency and AIDS. J Infect Dis. 1997; 176(5):1198-208. DOI: 10.1086/514113. View

Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V . BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012; 30(20):2522-9. DOI: 10.1200/JCO.2011.41.2452. View

Izraely S, Klein A, Sagi-Assif O, Meshel T, Tsarfaty G, Hoon D . Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol Lett. 2009; 130(1-2):107-14. DOI: 10.1016/j.imlet.2009.12.003. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

10.

Margolin K, Ernstoff M, Hamid O, Lawrence D, McDermott D, Puzanov I . Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13(5):459-65. DOI: 10.1016/S1470-2045(12)70090-6. View

11.

Davies M, Liu P, McIntyre S, Kim K, Papadopoulos N, Hwu W . Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2010; 117(8):1687-96. DOI: 10.1002/cncr.25634. View

12.

Preusser M, Capper D, Ilhan-Mutlu A, Berghoff A, Birner P, Bartsch R . Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012; 123(2):205-22. DOI: 10.1007/s00401-011-0933-9. View

13.

Salgado K, Toscani N, Silva L, Hilbig A, Barbosa-Coutinho L . Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin Exp Metastasis. 2007; 24(6):403-10. DOI: 10.1007/s10585-007-9077-7. View

14.

April C, Fan J . Gene expression profiling in formalin-fixed, paraffin-embedded tissues using the whole-genome DASL assay. Methods Mol Biol. 2011; 784:77-98. DOI: 10.1007/978-1-61779-289-2_6. View

15.

Davies M, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal Y . Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009; 15(24):7538-7546. PMC: 2805170. DOI: 10.1158/1078-0432.CCR-09-1985. View

16.

Kim S, Kim J, Park E, Lee J, Lin Q, Langley R . Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia. 2011; 13(3):286-98. PMC: 3050871. DOI: 10.1593/neo.11112. View

17.

Yang I, Tihan T, Han S, Wrensch M, Wiencke J, Sughrue M . CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 2010; 17(11):1381-5. PMC: 3064460. DOI: 10.1016/j.jocn.2010.03.031. View

18.

Park E, Kim S, Kim S, Yoon S, Leem S, Kim S . Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A. 2011; 108(42):17456-61. PMC: 3198333. DOI: 10.1073/pnas.1114210108. View

19.

Capper D, Berghoff A, Magerle M, Ilhan A, Wohrer A, Hackl M . Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2011; 123(2):223-33. DOI: 10.1007/s00401-011-0887-y. View

20.

Paulson K, Iyer J, Tegeder A, Thibodeau R, Schelter J, Koba S . Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol. 2011; 29(12):1539-46. PMC: 3082974. DOI: 10.1200/JCO.2010.30.6308. View